Overview

Corcept Therapeutics develops cortisol modulators to help regulate cortisol levels in the body, focusing on treatments for conditions like Cushing's syndrome, which is caused by excessive cortisol. Their main product, Korlym (mifepristone), is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome patients. The company distinguishes itself by investing heavily in research and development, having discovered over 1,000 selective cortisol modulators. Corcept aims to expand its product offerings while also supporting patient education and healthcare professional resources.

Simplify's Take

What believers are saying

• Corcept's stock is the best performing pharma stock in 2025.
• The MOMENTUM trial could expand Corcept's market reach.
• Corcept's NDA filing for a new drug shows active portfolio expansion.

What critics are saying

• Securities fraud investigations could harm Corcept's reputation and finances.
• Teva's antitrust lawsuit may lead to legal challenges for Corcept.
• Potential market share loss due to legal issues with Korlym.

What makes Corcept Therapeutics unique

• Corcept specializes in cortisol modulation, a niche with few competitors.
• Korlym is the first FDA-approved treatment for Cushing's syndrome.
• Corcept has discovered over 1,000 selective cortisol modulators.

Help us improve and share your feedback! Did you find this helpful?

YesNo